Background
==========

The induction of mucosal immunity is a crucial goal for HIV vaccines. DNA vaccines which are non-live/non-proliferating have had limited success in this area. Mucosal immune cell homing is in part controlled by a subset of chemokines (CCL27, CCL28 and CCL25). We hypothesized that a DNA vaccine encoding antigen and chemokine could induce mucosal immunity.

Methods
=======

Mice were systemically co-immunized with pHIV-1gag/pol and chemokine adjuvants. Rhesus macaques (n = 5/group) were immunized intramuscularly with antigenic plasmids plus/minus each chemokine. For rhesus optimized CCL27, CCL25, and CCL28 plasmids, optimized/consensus macaque pol and sooty mangabey consensus gag/env plasmids were generated.

Results
=======

Mice: Co-immunization with chemokines induced significant enhancement of HIV-1 specific CD8+ T cell IFN-gamma secretion in the periphery and TNF-alpha, IL-2 and IFN-gamma by gut lymphocytes. Co-immunization with mucosal chemokines augmented HIV-1-specific sIgA in sera/fecal samples. Similar immunogenicity data was observed to Influenza A/PR8/34 hemagglutanin plasmid including responses that neutralized virus and protected mice from morbidity/mortality associated with lethal mucosal challenge. Macaque: In the periphery, we observed significant IFN-gamma in all groups (\~6,000 SFU each). However intracellular cytokine staining on mucosal lymphocytes showed a trend toward an increase in CD8+T cells secreting TNF and IL-2 in CCL27 co-immunized macaques, levels greater than those observed in infected animals. Enhanced antigen-specific IgA was also detected in sera of chemokine-vaccinated macaques. A mucosal challenge is scheduled to determine if the functionality and phenotype of vaccine-induced immunity, either at the mucosa or periphery, is a driving determinant of protection.

Conclusion
==========

The results of this study will be critical to the development of an effective vaccine against HIV. This is the first example of the use of mucosal chemokines to influence a DNA vaccine strategy, suggesting a novel approach for manipulation of vaccine-induced immune responses. This work is supported by NIH funding (HIVRAD).
